Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pelcitoclax (APG-1252) is a powerful inhibitor of the Bcl-2 and Bcl-xl proteins, displaying significant antineoplastic and pro-apoptotic properties[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | $ 398.00 | |
5 mg | Inquiry | $ 1,120.00 | |
10 mg | Inquiry | $ 1,860.00 | |
25 mg | Inquiry | $ 3,860.00 | |
50 mg | Inquiry | $ 6,390.00 |
Description | Pelcitoclax (APG-1252) is a powerful inhibitor of the Bcl-2 and Bcl-xl proteins, displaying significant antineoplastic and pro-apoptotic properties[1]. |
In vitro | APG-1252 undergoes metabolic transformation into its reactive form, APG-1252-M1, which exhibits significant antitumor activity in (acute myeloid leukemia)[1]. |
In vivo | Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once a day; for 10days) treatment inhibits xenograft tumor growth more obviously than the other groups[1]. |
Molecular Weight | 1281.84 |
Formula | C57H66ClF4N6O11PS4 |
CAS No. | 1619923-36-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pelcitoclax 1619923-36-2 inhibitor inhibit